RT Journal Article
SR Electronic
T1 Scanning electron microscopy observations on the surface morphology of placenta villi from HIV-positive women having preterm birth while receiving antiretroviral therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.11.23294011
DO 10.1101/2023.08.11.23294011
A1 Obimbo, Moses M.
A1 Ochieng’, Shem
A1 Gesaka, Samwel R.
A1 Ogeng’o, Julius
YR 2023
UL http://medrxiv.org/content/early/2023/08/16/2023.08.11.23294011.abstract
AB Background Preterm birth is a significant global issue. Antiretroviral therapy (ART) use and human immunodeficiency virus (HIV) infection have both been linked in recent research as independent risk factors for preterm birth. Although there has been evidence linking preterm delivery to significant pathological alterations in the placenta, it is still unclear how exactly HIV and ART harm the placenta and raise the risk of prematurity. To explain the increased risk of preterm birth (PTB), we set out to describe the surface morphological alterations in placenta villi associated with HIV and ART.Methods and materials We collected and processed 160 placentas from 40 HIV-positive women on ART and 40 HIV-negative women who had preterm deliveries, 40 HIV-positive women and 40 HIV - negative women with term delivery in Nairobi, Kenya. The placenta biopsies were harvested, washed in phosphate buffer solution, and processed for scanning electron microscopy. The dried tissue was mounted onto specimen stubs, sputter coated with gold and visualized using Zeiss Merlin FESEM in-lens. Forty representative samples, 10 from each group, were randomly selected and examined by investigators who were blinded to maternal HIV serostatus.Results The average gestational age for preterm and term births was 34 and 39 weeks, respectively. The average age of the mothers of preterm and term babies was 26.8 + 4.6 years and 24.3 + 4.3 years, respectively. The villous core of the placenta from HIV-negative patients was covered with microvilli that varied in size and appearance, and there were hardly any residual red blood cells. Placenta from HIV-positive women with preterm birth had widespread damage with shrunken and wrinkled villi, predominant blunting of the microvilli, with attendant syncytiotrophoblast disruption, and significant erythrocyte adhesion within extensive fibrillar meshwork and on surface of the syncytium.Conclusion Our results show distinctive alterations in the placenta of HIV-positive mothers who gave birth prematurely, which may impair the syncytium’s ability to function normally. Microvilli blunting, syncytial disruptions, and syncytial erythrocyte adhesion might be the symptoms of a deeper biological process. Further work to understand the effect of HIV/ART on the syncytiotrophoblast in relation to prematurity is recommended.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval to conduct the study and permission to transport specimens was sought from the Kenyatta National Hospital/University of Nairobi Ethics and Research Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.